EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 (Novembre 2016) Hors série n°2 Med Sci (Paris), 32 (2016) 30-39 References
Free Access
Issue
Med Sci (Paris)
Volume 32, Novembre 2016
Les cahiers de myologie
Page(s) 30 - 39
Section Dossier
DOI https://doi.org/10.1051/medsci/201632s209
Published online 21 November 2016
  1. Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2010 ; 31 : 2715–2726. [CrossRef] [PubMed] [Google Scholar]
  2. Moretti A, Caron L, Nakano A, et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006 ; 127 : 1151–1165. [CrossRef] [PubMed] [Google Scholar]
  3. Van Berlo JH, Molkentin JD. Most of the dust has settled: cKit+ progenitor cells are an irrelevant source of cardiac myocytes in vivo. Circ Res 2016 ; 118 : 17–19. [CrossRef] [PubMed] [Google Scholar]
  4. Balber AE. Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine. Stem Cells 2011 ; 29 : 570–575. [CrossRef] [PubMed] [Google Scholar]
  5. Koninckx R, Daniels A, Windmolders S, et al. The cardiac atrial appendage stem cell: a new and promising candidate for myocardial repair. Cardiovasc Res 2013 ; 97 : 413–423. [CrossRef] [PubMed] [Google Scholar]
  6. Roehrich ME, Spicher A, Milano G, et al. Characterization of cardiac-resident progenitor cells expressing high aldehyde dehydrogenase activity. Biomed Res Int 2013 ; 2013 : 503047. [CrossRef] [PubMed] [Google Scholar]
  7. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 2015 ; 116 : 1413–1430. [CrossRef] [PubMed] [Google Scholar]
  8. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013 ; 61 : 2329–2338. [CrossRef] [PubMed] [Google Scholar]
  9. Chong JJ, Yang X, Don CW, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014 ; 510 : 273–277. [CrossRef] [PubMed] [Google Scholar]
  10. Catelain C, Riveron S, Papadopoulos A, et al. Myoblasts and embryonic stem cells differentially engraft in a mouse model of genetic dilated cardiomyopathy. Mol Ther 2013 ; 21 : 1064–1075. [CrossRef] [PubMed] [Google Scholar]
  11. Nussbaum J, Minami E, Laflamme MA, et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 2007 ; 21 : 1345–1357. [CrossRef] [PubMed] [Google Scholar]
  12. Menasché P, Vanneaux V, Fabreguettes JR, et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur Heart J 2015 ; 36 : 743–750. [CrossRef] [PubMed] [Google Scholar]
  13. Menasché P, Vanneaux V, Hagège A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J 2015 ; 36 : 2011–2017. [CrossRef] [PubMed] [Google Scholar]
  14. Menasché P. The future of stem cells: should we keep the stem and skip the cells?. J Thorac Cardiovasc Surg 2016 ; 152 : 345–349. [CrossRef] [PubMed] [Google Scholar]
  15. Menasché P, Vanneaux V. Stem cells for the treatment of heart failure. Curr Res Transl Med 2016 ; 64 : 97–106. [CrossRef] [PubMed] [Google Scholar]
  16. Silvestre JS, Menasché P. The evolution of the stem cell theory for heart failure. EBioMedicine 2015 ; 2 : 1871–1879. [CrossRef] [PubMed] [Google Scholar]
  17. Bobis-Wozowicz S, Kmiotek K, Sekula M, et al. Human induced pluripotent stem cell-derived microvesicles transmit RNAs and proteins to recipient mature heart cells modulating cell fate and behavior. Stem Cells 2015 ; 33 : 2748–2761. [CrossRef] [PubMed] [Google Scholar]
  18. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2014 ; 2 : 606–619. [CrossRef] [PubMed] [Google Scholar]
  19. Menasché P, Alfieri O, Janssens S, et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008 ; 117 : 1189–1200. [CrossRef] [PubMed] [Google Scholar]
  20. Fisher SA, Doree C, Mathur A, et al. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res 2015 ; 116 : 1361–1377. [CrossRef] [PubMed] [Google Scholar]
  21. Harvey E, Fisher SA, Doree C, et al. Current evidence of the efficacy of cell-based therapies in heart failure. Circ J 2015 ; 79 : 229–236. [CrossRef] [PubMed] [Google Scholar]
  22. Kandala J, Upadhyay GA, Pokushalov E, et al. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol 2013 ; 112 : 217–225. [CrossRef] [PubMed] [Google Scholar]
  23. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013 ; 113 : 810–834. [CrossRef] [PubMed] [Google Scholar]
  24. Nowbar AN, Mielewczik M, Karavassilis M, et al. DAMASCENE writing group. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. Br Med J 2014 ; 348 : g2688. [CrossRef] [PubMed] [Google Scholar]
  25. Gho JM, Kummeling GJ, Koudstaal S, et al. Cell therapy, a novel remedy for dilated cardiomyopathy? A systematic review. J Card Fail 2013 ; 19 : 494–502. [Google Scholar]
  26. Smith DM. Assessing commercial opportunities for autologous and allogeneic cell-based products. Regen Med 2012 ; 7 : 721–732. [CrossRef] [PubMed] [Google Scholar]
  27. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012 ; 308 : 2369–2379. [CrossRef] [PubMed] [Google Scholar]
  28. Jansen Of Lorkeers SJ, Eding JE, Vesterinen HM, et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res 2015 ; 116 : 80–86. [CrossRef] [PubMed] [Google Scholar]
  29. Jackman CP, Shadrin IY, Carlson AL, et al. Human cardiac tissue engineering: from pluripotent stem cells to heart repair. Curr Opin Chem Eng 2015 ; 7 : 57–64. [CrossRef] [PubMed] [Google Scholar]
  30. Bellamy V, Vanneaux V, Bel A, et al. Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold. J Heart Lung Transplant 2015 ; 34 : 1198–1207. [CrossRef] [PubMed] [Google Scholar]
  31. Segers VF, Lee RT. Biomaterials to enhance stem cell function in the heart. Circ Res 2011 ; 109 : 910–922. [CrossRef] [PubMed] [Google Scholar]
  32. Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: state of the art. Circ Res 2014 ; 114 : 354–367. [CrossRef] [PubMed] [Google Scholar]
  33. Kupfer ME, Ogle BM. Advanced imaging approaches for regenerative medicine: emerging technologies for monitoring stem cell fate in vitro and in vivo. Biotechnol J 2015 ; 10 : 1515–1528. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.